Bicycle Therapeutics remains a high-risk, binary-outcome biotechnology play heavily reliant on its proprietary peptide platform to drive future value. While the company maintains a robust liquidity position, the lack of sustainable commercial revenue and persi...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | -$0.72-27.6% vs -$0.56 | $629,000-85.1% vs $4M |
Q2 2026 Apr 30, 2026 | -$0.87-67.3% vs -$0.52 | $887,000-88.2% vs $8M |
Q2 2026 Mar 17, 2026 | -$0.29+69.1% vs -$0.94 | $48M+581.6% vs $7M |
Q4 2025 Oct 30, 2025 | -$0.85+22.0% vs -$1.09 | $12M+65.8% vs $7M |
Visa is set to acquire Israel-based fraud intelligence company BioCatch for $2.4 billion. The all-cash deal, announced Monday (Aug. 3) aims to complement Visa's cyber, fraud, risk and security solutions and help clients protect themselves and customers from a growing range of fraud-related threats.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. “We are pleased with the progress we made during the second quarter. Our financial discipline with refined focus on nuzefatide pevedotin and our nex.
Benchmark BCYC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bicycle Therapeutics plc (BCYC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.60 | $249.82M | -1.14 | 105.77% | -301.66% | -31.21% | — | |
| $2.72 | $188.14M | -1.28 | — | — | -51.01% | — | |
| $23.52 | $15.73M | -3.08 | 3.7% | -353% | -87.96% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $52.95 | $4.77B | -51.41 | — | — | -20.02% | — | |
| $34.19 | $2.03B | -4.80 | 48.03% | -418.24% | -35.67% | — |
Bicycle Therapeutics plc (BCYC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bicycle Therapeutics plc (BCYC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 18, 2026·SEC
May 21, 2026·SEC
Get notified when BCYC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bicycle Therapeutics plc (BCYC) stock FAQ — growth, dividends, profitability & financials explained
Bicycle Therapeutics plc (BCYC) reported $61.2M in revenue for fiscal year 2025.
Bicycle Therapeutics plc (BCYC) grew revenue by 105.8% over the past year. This is strong growth.
Bicycle Therapeutics plc (BCYC) reported a net loss of $190.4M for fiscal year 2025.
Bicycle Therapeutics plc (BCYC) has a return on equity (ROE) of -31.2%. Negative ROE indicates the company is unprofitable.
Bicycle Therapeutics plc (BCYC) had negative free cash flow of $205.6M in fiscal year 2025, likely due to heavy capital investments.
